N@N

Cascadia Investments, Inc.: Cascadia Investments, Inc. Announces Acquisition of a Boutique Advertising Network

^{Published on 2009-08-18 06:35:14, Last Modified on 2009-08-18 06:35:22 - Market Wire}
 

TACOMA, WA--(Marketwire - August 18, 2009) - Cascadia Investments, Inc. (PINKSHEETS: [ CDIV ]) announces the acquisition of [ www.pharmads.com ], a boutique advertising network specifically designed for use by advertisers and publishers of pharmaceutical-related brands, sites, and products. In the last seven years, with changes in FDA guidelines, expenditures on direct-to-consumer pharmaceutical advertising have quintupled. Currently, more than $30 billion is spent annually marketing pharmaceuticals, a figure that is expected to grow as drug companies search for new advertising outlets.

Pharmads.com is the first in a series of boutique ad networks that Cascadia plans to launch in the coming months, each specializing in a specific niche market. In addition, the company plans to develop additional supplemental sites that will further diversify each niche market.

Please check out Cascadia's new website at [ www.cascadiainteractive.com ] for the latest details on all of our Internet properties.

About Cascadia Investments, Inc.

Cascadia Investments, Inc. (PINKSHEETS: [ CDIV ]) is a publicly traded, real estate development company operating in the Pacific Northwest. The company's principal objective is to create equity and long-term earnings growth through the acquisition and development of undervalued real estate and cutting edge internet properties.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Except for historical information, the forward looking matters discussed in this news release are subject to certain risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements including, but not limited to, the Company's liquidity and the ability to obtain financing, the timing of regulatory approvals, uncertainties related to corporate partners or third parties, product liability, the dependence on third parties for manufacturing and marketing, patent risk, copyright risk, competition, and the early stage of products being marketed or under development, as well as other risks indicated from time to time in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events.